Berna Biotech and Onyvax announce collaboration
Berna Biotech Ltd (SWX: BBIN) and Onyvax Ltd today announced
the formation of a collaboration. Under the terms of contract,
Berna will produce phase III clinical trials batches of Onyvax-P,
Onyvax’s Cell Vaccine against prostate cancer.
Onyvax-P contains three cell lines that represent different
stages of prostate cancer. The cell lines are irradiated and
so cannot grow or divide. Onyvax designed its vaccine to induce
a powerful immune response against a broad range of prostate
cancer-associated antigens without the severe side effects often
associated with conventional cancer therapies.
This production agreement provides Berna with the opportunity
to expand its expertise into another promising therapeutic area.
The collaboration provides Onyvax to share Berna’s broad
experience in producing vaccines to the highest standard.
No financial details were disclosed.
About Berna Biotech
Berna Biotech Ltd (Swiss Exchange: BBIN) develops, produces
and markets vaccines and immunotherapeutics for private and public
Headquartered in Bern, Switzerland, with subsidiaries in Europe and Korea,
Berna Biotech employs app. 900 people. A range of novel and validated proprietary
technology platforms support a strong product portfolio. The company markets
its primary vaccines products in the hepatitis B, respiratory and travel franchises,
and has a broad development pipeline. Development is supported through alliances
with academic and commercial partners.
In the first half 2003, Berna Biotech achieved a net sales of 158.5 million
CHF and an EBITDA (earnings before interest, taxes, depreciation and amortisation)
of 63.7 million CHF.
Further information on Berna can be found at www.bernabiotech.com
Onyvax is a biotechnology company developing novel cancer therapies
that harness the selective power of the immune system to seek
and destroy tumour cells.
Founded in 1997, Onyvax has three product candidates in clinical
trials designed for the treatment of prostate and other cancers.
Onyvax’s lead products are based on combinations of inactivated
cell lines that induce immune responses to a broad spectrum of
tumour targets. For each cancer type, Onyvax generates banks
of proprietary cell lines representative of different stages
of the disease. The vaccines are manufactured in bulk under standardised
Onyvax is committed to the commercialisation of new therapies
that significantly prolong survival while maintaining a high
quality of life for cancer patients. The Company is based in
London and has collaborations with leading institutions in Europe
and the US.
Further information on Onyvax can be found at www.onyvax.com